

# Global Influenza Surveillance and Response System (GISRS)

## Situation update on integrated sentinel surveillance of influenza and SARS-CoV-2 in SEAR Member States


(As of September 2025, reported to FluMart of GISRS)

Infectious Hazard Management (IHM)

WHO Health Emergency Programme

[SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, [SEAR](#)



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09 /2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, [SEAR](#)



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09 /2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

Number of ILI/SARI specimens processed for testing by week and year, [SEAR](#)



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of [09/2025](#)  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, [SEAR](#)



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025


WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

# Number and the percentage of ILI/SARI specimens positive for SARS- COV-2, [SEAR](#)



\*Includes Member states doing SARS-COV2 testing part of Influenza sentinel surveillance.

## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, Bangladesh



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09 /2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, [Bangladesh](#)



Sub-types

Specimen test

ILI


SARI

SARS COV2


Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)



Number of ILI/SARI specimens processed for testing by week and year, [Bangladesh](#)



# Number of specimens positive for influenza by subtypes and the percentage positive, Bangladesh



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, [Bhutan](#)



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, [Bhutan](#)



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

# Number of ILI/SARI specimens processed for testing by week and year, Bhutan



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

Number of specimens positive for influenza by subtypes and the percentage positive, Bhutan



Sub-types

Specimen test


ILI

SARI


SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, [DPR Korea](#)



Number of ILI/SARI specimens processed for testing by week and year, [DPR Korea](#)



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)



## Number of specimens positive for influenza by subtypes and the percentage positive, DPR Korea



● A/H1N1pdm09 ● A/H1 ● A/H3 ● A/H5 ● A (Unsubtyped) ● B Yamagata ● B Victoria ● B (Unsubty... — % Positive

Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

# Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, India



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, [India](#)



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

Number of ILI/SARI specimens processed for testing by week and year, [India](#)



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of [09/2025](#)  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, India



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, Maldives



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

Number of specimens positive for influenza by subtypes and the percentage positive, Maldives



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, [Myanmar](#)



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)



Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, Myanmar



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, Myanmar



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, Myanmar



Sub-types

Specimen test

ILI


SARI

SARS COV2


Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

# Number of influenza-like illness (ILI) cases , [Nepal](#)



## Number of severe acute respiratory infection (SARI) cases , Nepal



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

Number of ILI/SARI specimens processed for testing by week and year, [Nepal](#)



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of [09/2025](#)  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, Nepal



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, [Sri Lanka](#)



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)



# Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, [Sri Lanka](#)



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of ILI/SARI specimens processed for testing by week and year, [Sri Lanka](#)



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of [09/2025](#)  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtype and the percentage positive, Sri Lanka



Sub-types

Specimen test

ILI


SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

# Number and the proportion of influenza-like illness (ILI) cases per 1 000 outpatients, Thailand



Sub-types

Specimen test


ILI

SARI


SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

Number and the proportion of severe acute respiratory infection (SARI) cases per 100 inpatients, [Thailand](#)



Number of ILI/SARI specimens processed for testing by week and year, Thailand



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, Thailand



Sub-types

Specimen test


ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

## Number of specimens positive for influenza by subtypes and the percentage positive, Timor-Leste



Sub-types

Specimen test

ILI

SARI


SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 12/2025

WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)



## Number of ILI/SARI specimens processed for testing by week and year, Timor-Leste



Sub-types

Specimen test

ILI

SARI

SARS COV2

Data Source: Global Influenza Surveillance and Response System (GISRS): FluMart as of 09/2025  
WHO/SEARO/WHE/Infectious Hazard Management | For feedback/inquiry please write to: [SeFlu@who.int](mailto:SeFlu@who.int)

If you have any comment or suggestion  
Please write to [SeFlu@who.int](mailto:SeFlu@who.int)